Samer A. Al'Hadidi, MD, MS, reviewed the benefits of cilta-cel in the subgroup analysis of CARTITUDE-4 in patients with ...

Yufei Liu, MD, PhD, discussed the importance of careful data interpretation to accurately assess the efficacy of new ...

Jacob E. Berchuck, MD, discussed research behind using a blood-based liquid biopsy in prostate cancer and findings presented ...

The FDA has granted orphan drug designation to namodenoson (CF102) in pancreatic cancer. Orphan drug designation provides Can ...

Mirvetuximab soravtansine (Elahere) is an antibody-drug conjugate designed to treat ovarian cancer. It works by binding to folate receptor-alpha (FRα). This binding delivers a potent anticancer drug ...

During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of ...

The first patient in a phase 1/2 trial investigating a novel agent for the treatment of non–small cell lung cancer has been ...

Ana Baramidze, MD, PhD, discussed 5-year follow-up results from the EMPOWER-Lung study evaluating cemiplimab vs chemotherapy ...

The KEYNOTE-689 study evaluating pembrolizumab in this patient population met its primary end point of event-free survival.

The FDA has granted VLS-1488 fast track designation in patients with platinum-resistant high-grade serous ovarian cancer.

The SunRISe-2 trial evaluating TAR-200 combined with cetrelimab vs chemoradiation in muscle-invasive bladder cancer has been ...

Jaime Merchan, MD, discusses what the potential clinical implications or takeaways for colleagues are based on findings from ...